Tristel: We Celebrated The 3p Special Dividend While Sitting In A Marquee Out In The Car Park

26 July 2016
By Maynard Paton

Long update on Tristel (TSTL).

Event: Shareholder open day, presentation and trading update for the year ending 30 June 2016 published 21 July 2016

Summary: A very useful shareholder event that accompanied a better-than-expected trading update. The bright spot was recovering UK revenue, although management oddly could not explain why the rebound occurred. Another special dividend and the purchase of an Australian distributor were welcome developments, too. Plenty of interesting snippets were disclosed during the day, including certain products having their prices doubled. However, I still disagree with management about past disclosures. I continue to hold. 

Read moreTristel: We Celebrated The 3p Special Dividend While Sitting In A Marquee Out In The Car Park

Tristel: These Results Were A Letdown And I Have Been Selling

24 February 2016
By Maynard Paton

Quick update on Tristel (TSTL).

Event: Interim results published 24 February

Summary: Oh dear — these results were something of a letdown :-( It seems TSTL’s projections of c%15 revenue growth have been dropped as UK turnover starts to stall. At least now we know why December’s AGM statement never mentioned sales! A startling £1m share-based payment and a signal for a pedestrian 5% dividend lift were other features I did not expect. Though I still hold TSTL, I have been selling during recent weeks and sold more today.

Read moreTristel: These Results Were A Letdown And I Have Been Selling

My Portfolio: Year In Review 2015

01 January 2016
By Maynard Paton

Happy New Year!

I trust you enjoyed the festive break and are now raring to do battle with the market for another twelve months!

This first Blog post of 2016 provides a short ‘year-in-review’ of each of my current portfolio holdings.

As I mentioned at the start of 2015, I find writing such reviews extremely useful — not least because it encourages me to double-check my investment logic to ensure I am still invested for all the right reasons!

Read moreMy Portfolio: Year In Review 2015

Tristel: This Share Now Represents 18% Of My Portfolio

15 December 2015
By Maynard Paton

Quick update on Tristel (TSTL).

Event: AGM statement published 15 December

Summary: It looks as if this medical-wipes specialist is all set to surpass profit expectations for 2016, and probably its own targets for 2017 as well. Throw in some new (to me) speculation about deals with FTSE multinationals, and it’s no wonder the share price has performed so well of late. In fact, this holding has grown to become 18% of my portfolio — and I must admit to some nerves given the premium growth rating. Anyway, I continue to hold.

Read moreTristel: This Share Now Represents 18% Of My Portfolio

Tristel: The Shares Have Rallied And I Am Holding On

13 October 2015
By Maynard Paton

Quick update on Tristel (TSTL).

Event: Final results and annual report published 12 October

Summary: It’s always nice to see your largest holding issue good figures and watch the share price rally strongly! These results met or exceeded my expectations, with bumper H2 margins, good all-round revenue growth and upbeat management commentary. The firm’s repeat-purchase and patent-protected products continue to promise further growth — notably in the United States — and the current valuation reflects such optimism. I continue to hold. 

Read moreTristel: The Shares Have Rallied And I Am Holding On

Tristel: I’m Still Projecting 15%-Plus Annual Returns

22 May 2015
By Maynard Paton

Quick update on Tristel (TSTL).

Event: Trading update published 21 May.

Summary: At last — one of my shares has issued an ‘ahead of expectations’ trading statement! TSTL’s medical wipes appear to be selling very well and second-half profits now seem set to grow by 35%. There could be further upside, too, if TSTL’s past ‘sandbagging’ form is anything to go by. My valuation sums still suggest annual returns of 15%-plus could be earned. I continue to hold. 

Read moreTristel: I’m Still Projecting 15%-Plus Annual Returns

Tristel: Is There A Further 46% Upside?

25 February 2015
By Maynard Paton

Here’s a an update on Tristel (TSTL).

Event: Half-year results published 25 February.

Summary: Figures met my expectations, showing good all-round progress. Management commentary noticeably upbeat — confidence underlined by first RNS mentions of group sales target and ‘North America’. Firm’s healthcare products remain attractive to investors — repeat purchase and patent protected. Share-price upside could be attractive if growth forecasts come good. I continue to hold.

Read moreTristel: Is There A Further 46% Upside?

Tristel Plc: Why My Latest Purchase Could Double Within 3 Years

20 March 2014
By Maynard Paton

Today I am going to tell you about my latest purchase and why I believe the share price could double within three years.

The company is Tristel (LON: TSTL), a £20m supplier of heavy-duty hospital disinfectants. I’ve been a buyer since December 2013 and my average entry price is 46p. If all goes to plan, my projections suggest the price could trade beyond 100p by 2017.

Read moreTristel Plc: Why My Latest Purchase Could Double Within 3 Years